PLoS ONE (Dec 2010)

Oral methylthioadenosine administration attenuates fibrosis and chronic liver disease progression in Mdr2-/- mice.

  • M Ujue Latasa,
  • Carmen Gil-Puig,
  • Maite G Fernández-Barrena,
  • Carlos M Rodríguez-Ortigosa,
  • Jesús M Banales,
  • Raquel Urtasun,
  • Saioa Goñi,
  • Miriam Méndez,
  • Sara Arcelus,
  • Nerea Juanarena,
  • Juan A Recio,
  • Sophie Lotersztajn,
  • Jesús Prieto,
  • Carmen Berasain,
  • Fernando J Corrales,
  • Jon Lecanda,
  • Matías A Avila

DOI
https://doi.org/10.1371/journal.pone.0015690
Journal volume & issue
Vol. 5, no. 12
p. e15690

Abstract

Read online

BackgroundInflammation and fibrogenesis are directly related to chronic liver disease progression, including hepatocellular carcinoma (HCC) development. Currently there are few therapeutic options available to inhibit liver fibrosis. We have evaluated the hepatoprotective and anti-fibrotic potential of orally-administered 5'-methylthioadenosine (MTA) in Mdr2(-/-) mice, a clinically relevant model of sclerosing cholangitis and spontaneous biliary fibrosis, followed at later stages by HCC development.MethodologyMTA was administered daily by gavage to wild type and Mdr2(-/-) mice for three weeks. MTA anti-inflammatory and anti-fibrotic effects and potential mechanisms of action were examined in the liver of Mdr2(-/-) mice with ongoing fibrogenesis and in cultured liver fibrogenic cells (myofibroblasts).Principal findingsMTA treatment reduced hepatomegaly and liver injury. α-Smooth muscle actin immunoreactivity and collagen deposition were also significantly decreased. Inflammatory infiltrate, the expression of the cytokines IL6 and Mcp-1, pro-fibrogenic factors like TGFβ2 and tenascin-C, as well as pro-fibrogenic intracellular signalling pathways were reduced by MTA in vivo. MTA inhibited the activation and proliferation of isolated myofibroblasts and down-regulated cyclin D1 gene expression at the transcriptional level. The expression of JunD, a key transcription factor in liver fibrogenesis, was also reduced by MTA in activated myofibroblasts.Conclusions/significanceOral MTA administration was well tolerated and proved its efficacy in reducing liver inflammation and fibrosis. MTA may have multiple molecular and cellular targets. These include the inhibition of inflammatory and pro-fibrogenic cytokines, as well as the attenuation of myofibroblast activation and proliferation. Downregulation of JunD and cyclin D1 expression in myofibroblasts may be important regarding the mechanism of action of MTA. This compound could be a good candidate to be tested for the treatment of (biliary) liver fibrosis.